Comparison of orlistat treatment and placebo in obese type 2 diabetic patients

Author： Derosa Giuseppe Maffioli Pamela Salvadeo Sibilla AT Ferrari Ilaria Gravina Alessia Mereu Roberto D'Angelo Angela Fogari Elena Palumbo Ilaria Randazzo Sabrina Cicero Arrigo FG

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.12, 2010-08, pp. : 1971-1982

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus

By Maetzel A.

PharmacoEconomics, Vol. 21, Iss. 7, 2003-01 ,pp. : 501-512

Adis International

Access to resources Recommend Favorite

Orlistat: In the Prevention and Treatment of Type 2 Diabetes Mellitus

By Keating G.M. Jarvis B.

Drugs, Vol. 61, Iss. 14, 2001-01 ,pp. : 2107-2119

Adis International

Access to resources Recommend Favorite

Orlistat in the treatment of Type 2 diabetes mellitus

By Jneidi Muna Kelley David E

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 599-605

Informa Healthcare

Access to resources Recommend Favorite

The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes

By Nelson Robert H Miles John M

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 14, 2005-11 ,pp. : 2483-2491

Informa Healthcare

Access to resources Recommend Favorite

Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes

By Cincotta A.H. Meier A.H. Cincotta M.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1683-1707

Informa Healthcare

Access to resources Recommend Favorite